Eleanor Davina, DO
Internal Medicine · Mount Dora, FLNPI 1477556785
Payments from drug & device makers
Across 238 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$525
- Novo Nordisk$508
- GSK$316
- AstraZeneca$260
- Pfizer$227
- Amgen$216
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,707100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $525 |
| Novo Nordisk | 38 | $508 |
| GSK | 20 | $316 |
| AstraZeneca | 17 | $260 |
| Pfizer | 13 | $227 |
| Amgen | 13 | $216 |
| Lilly USA, LLC | 12 | $181 |
| Boehringer Ingelheim | 22 | $180 |
| Sanofi-aventis U.S. LLC | 8 | $143 |
| Dexcom, Inc. | 6 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $115 |
| Bayer | 5 | $98 |
| Merck | 5 | $90 |
| Axsome Therapeutics, Inc. | 2 | $61 |
| Johnson & Johnson | 3 | $58 |
| Novartis | 4 | $57 |
| Astellas Pharma US Inc | 3 | $53 |
| Exact Sciences | 3 | $52 |
| Eisai Inc. | 2 | $44 |
| Revance Therapeutics, Inc. | 1 | $39 |
| Antares Pharma, Inc. | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Radius Health, Inc. | 1 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Millicent US Inc | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Organogenesis Inc. | 1 | $13 |
| Abbott | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$3,719 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $199,383 |
| EliquisApixaban | 162 | $194,001 |
| MounjaroTirzepatide | 82 | $86,362 |
| JardianceEmpagliflozin | 74 | $84,029 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $68,503 |
| FarxigaDapagliflozin Propanediol | 31 | $43,827 |
| XareltoRivaroxaban | 39 | $38,832 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $35,861 |
| MyrbetriqMirabegron | 33 | $32,635 |
| JanuviaSitagliptin Phosphate | 34 | $23,745 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $22,794 |
| TrulicityDulaglutide | 12 | $22,748 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $22,625 |
| LinzessLinaclotide | 21 | $21,837 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $18,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $227 | $201,062176 claims |
| Novo NordiskOzempic | $508 | $199,383160 claims |
| Lilly USA, LLCMounjaro, Trulicity | $181 | $109,11094 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $316 | $106,926125 claims |
| Boehringer IngelheimJardiance | $180 | $84,02974 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $260 | $74,81075 claims |
| Johnson & JohnsonXarelto | $58 | $38,83239 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $32,63533 claims |
| AbbVieLinzess, Synthroid | $525 | $32,313153 claims |
| MerckJanuvia, Janumet | $90 | $31,39646 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $12,76717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Mount Dora
- Shirley NagelMount Dora$4.3M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.